Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

10

Revenue 2017

Amgen

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Amgen's 2013 sales performance.

Amgen

Amgen pays $900m upfront to acquire Teneobio’s antibody assets, R&D technologies

Amgen pays $900m upfront to acquire Teneobio’s antibody assets, R&D technologies

Amgen will gain antibody technologies designed to discover and develop new molecules with broad applications across therapeutic areas. ... Teneobio’s own novel T cell engager platform will complement the BiTE platform, Amgen said in a statement.

FDA grants priority review for AZ, Amgen’s tezepelumab for asthma

FDA grants priority review for AZ, Amgen’s tezepelumab for asthma The US Food and Drug Administration (FDA) has accepted AstraZeneca (AZ) and Amgen’s submission for their investigational asthma drug tezepelumab and granted a priority review for the therapy. . ... AZ and Amgen’s drug acts further upstream in the

US Supreme Court rebuffs Sandoz’s Enbrel biosimilar patent case

US Supreme Court rebuffs Sandoz’s Enbrel biosimilar patent case Erelzi references Amgen’s blockbuster arthritis drug Enbrel (etanercept) – Sandoz had been hoping to launch the biosimilar as a ‘more affordable’ treatment option for US patients. ... This decision also ruled against Sandoz, with the Federal

AZ, Amgen file first-in-class asthma drug with the FDA

AZ, Amgen file first-in-class asthma drug with the FDA AstraZeneca (AZ) and Amgen have submitted a biologic license application (BLA) for their first-in-class asthma drug tezepelumab to the US Food and Drug Administration (FDA). ... AZ and Amgen are seeking approval for tezepelumab for the treatment of

Alexion and NICE agree confidential discount for Ultomiris use on the NHS

Alexion and NICE agree confidential discount for Ultomiris use on the NHS In 2020, Alexion reached a patent settlement with Amgen, preventing a biosimilar version of the drug from entering the US marketing until 2025.

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

Committing time to making meaningful connections - top 5 tips
Read the second blog of the series looking at key barriers to effective patient engagement in pharma...
News:
Senior Analytics Specialist joins Research Partnership...
Digital technologies: Pharma’s answer to achieving net zero emissions?
...